Friday, August 15, 2025
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Cancer

FDA approves drug targeting Johns Hopkins-discovered brain cancer gene mutation

August 7, 2024
in Cancer
Reading Time: 3 mins read
0
Bbrain cancer drug targets the IDH mutation
66
SHARES
597
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

FOR IMMEDIATE RELEASE

Bbrain cancer drug targets the IDH mutation

Credit: Elizabeth Cook

ADVERTISEMENT

FOR IMMEDIATE RELEASE

A new drug for treatment of a type of brain cancer, called IDH-mutant low-grade glioma, was approved Aug. 6 by the U.S. Food and Drug Administration (FDA). The promising new drug stems from a 2008 genetic discovery made at the Johns Hopkins Kimmel Cancer Center. 

The drug, called vorasidenib, is a targeted cancer therapy that works by inhibiting the activity of a mutated gene called IDH, slowing the growth of the cancer.  The gene was identified by Bert Vogelstein, M.D., and team at the Johns Hopkins Kimmel Cancer Center’s Ludwig Center in 2008 when they became the first to map the genetic blueprint for brain cancer. The blueprint was considered the most comprehensive genetic analysis for any tumor type, evaluating all known protein-encoding genes in brain cancer. 

The researchers found that the IDH gene—which had never been suspected to be involved in any tumor type—was frequently mutated in a subset of brain cancers. 

“IDH is the poster child for cancer genome sequencing, and it illustrates the importance of basic research,” says Vogelstein, the Clayton Professor of Oncology, Howard Hughes Medical Institute investigator, and co-director of the Ludwig Center. “The history of medicine shows that when a disease is understood, it eventually becomes manageable. It may not be immediately evident, but in time, as in this case, such discoveries result in better treatment for patients.” 

Vogelstein and team’s genetic discoveries ushered in what is known as precision, or individualized, cancer medicine in which therapies are targeted to the unique genetic makeup of each patient’s cancer. 

In June 2023, findings from a multicenter, phase 3 clinical trial of vorasidenib in 331 patients with IDH-mutant low grade glioma was published in the New England Journal of Medicine and concluded that patients with grade 2 IDH-mutant glioma who received the drug had significantly improved progression-free survival and that the therapy delayed the time to the next intervention compared to patients who received a placebo. The trial was sponsored by the international pharmaceutical company Servier, who is bringing vorasidenib to market. 

In addition to this newly FDA-approved drug, the IDH gene discovery led to a new classification of gliomas, differentiating cancers with an IDH mutation that have overall better outcome and response to treatment from very aggressive gliomas without an IDH mutation, including glioblastoma, the most common primary brain cancer in adults. It has also paved the way for additional studies in other types of brain cancer. 

Approximately 80% of low-grade gliomas contain an IDH mutation, according to the National Cancer Institute. They include IDH-mutant astrocytoma and oligodendroglioma, and they occur most commonly in younger adults. Low grade gliomas tend to be slower growing and are associated with longer survival than aggressive, high-grade gliomas. 

Treatments include surgery to remove as much of the tumor as possible, followed by radiation and chemotherapy to attack remaining cancer cells. In some patients, the addition of the IDH inhibitor could delay the need for radiation therapy and chemotherapy. 

“The possibility of delaying radiation therapy and chemotherapy with this drug could be beneficial to select patients with slow growing IDH-mutant gliomas,” says Matthias Holdhoff, M.D., Ph.D., co-director of the Johns Hopkins Kimmel Cancer Center brain tumor program and a co-investigator on the 2023 clinical trial. “I believe we are looking at a new standard of care option for these types of tumors.” 

The Johns Hopkins University holds patents related to the IDH discovery, which have been licensed by Servier Laboratories. As a result of this licensing agreement, the University and its inventors, including Dr. Bert Vogelstein, are entitled to royalty distributions related to the IDH discovery. In addition, Dr. Matthias Holdhoff is a paid advisor to Servier, which provided funding for the study described in this press release.



Share26Tweet17
Previous Post

Researchers show pesticide contamination is more than apple skin deep

Next Post

LOINC® semiannual release: Global partners collaborate to enhance semantic interoperability with health terminology updates

Related Posts

blank
Cancer

Two Weill Cornell Medicine Scientists Honored with 2025 Pew Awards

August 15, 2025
blank
Cancer

Innovative Network Offers Promising Advances in Predicting Health Issues in Dogs

August 15, 2025
blank
Cancer

Adaptive Trial Explores QBS72S for Brain Mets

August 15, 2025
blank
Cancer

Scientists Identify Dementia-Like Behavior in Pre-Cancerous Cells

August 15, 2025
blank
Cancer

Epigenetic Duo Drives Cell Fate and Disease: Unraveling Double Trouble

August 14, 2025
blank
Cancer

Huntsman Cancer Institute Leaders Propel Theranostics Innovation to Revolutionize Cancer Treatment

August 14, 2025
Next Post
LOINC® semiannual release: Global partners collaborate to enhance semantic interoperability with health terminology updates

LOINC® semiannual release: Global partners collaborate to enhance semantic interoperability with health terminology updates

  • Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27533 shares
    Share 11010 Tweet 6881
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    947 shares
    Share 379 Tweet 237
  • Bee body mass, pathogens and local climate influence heat tolerance

    641 shares
    Share 256 Tweet 160
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    507 shares
    Share 203 Tweet 127
  • Warm seawater speeding up melting of ‘Doomsday Glacier,’ scientists warn

    310 shares
    Share 124 Tweet 78
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • Lehigh University’s Martin Harmer Recognized Among the Top 10 Global Science Breakthroughs of 2025 by Falling Walls Foundation
  • Two Weill Cornell Medicine Scientists Honored with 2025 Pew Awards
  • Monell Center Researchers Unveil Latest Discoveries at International Consumer Sensory Science Conference
  • Boosting Grain Yields: How Science and Technology Are Transforming Agriculture

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 4,859 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine

Discover more from Science

Subscribe now to keep reading and get access to the full archive.

Continue reading